K203103 is an FDA 510(k) clearance for the Synapse 3D, Synapse 3D Base Tools v6.1. Classified as System, Image Processing, Radiological within the LLZ classification (a category encompassing advanced image processing and PACS-adjacent software), Class II - Special Controls.
Submitted by Fujifilm Corporation (Tokyo, JP). The FDA issued a Cleared decision on February 9, 2021 after a review of 118 days - within the typical 510(k) review window.
This device falls under the Radiology FDA review panel, regulated under 21 CFR 892.2050 - the FDA radiology and imaging software oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Incremental AI imaging tool. Moderate equivalence dependency. Overall, this clearance reflects a predicate-aligned approval typical of modern AI radiology extensions - not a novel clinical breakthrough, but a validated iteration within an established regulatory category.
View all Fujifilm Corporation devices